Literature DB >> 11447205

Interleukin-6 deficiency influences cytokine expression in susceptible BALB mice infected with Leishmania major but does not alter the outcome of disease.

R G Titus1, G K DeKrey, R V Morris, M B Soares.   

Abstract

Since interleukin-6 (IL-6) may promote Th2 responses, we infected BALB IL-6-deficient (IL-6(-/-)) mice with Leishmania major. There was not a significant difference between the courses of infection (lesion size and parasite burden) in IL-6(-/-) and wild-type mice, but IL-6(-/-) mice expressed lower levels of Th2- and Th1-associated cytokines.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11447205      PMCID： PMC98619          DOI： 10.1128/IAI.69.8.5189-5192.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  26 in total

1.  IL-6 is required for the development of Th1 cell-mediated murine colitis.

Authors:  M Yamamoto; K Yoshizaki; T Kishimoto; H Ito
Journal:  J Immunol       Date:  2000-05-01       Impact factor: 5.422

2.  Role of IL-6 in directing the initial immune response to schistosome eggs.

Authors:  A C La Flamme; A S MacDonald; E J Pearce
Journal:  J Immunol       Date:  2000-03-01       Impact factor: 5.422

3.  The absence of IL-6 does not affect Th2 cell development in vivo, but does lead to impaired proliferation, IL-2 receptor expression, and B cell responses.

Authors:  A C La Flamme; E J Pearce
Journal:  J Immunol       Date:  1999-05-15       Impact factor: 5.422

Review 4.  TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties.

Authors:  T R Mosmann; R L Coffman
Journal:  Annu Rev Immunol       Date:  1989       Impact factor: 28.527

Review 5.  Cytokines in parasitic diseases: the example of cutaneous leishmaniasis.

Authors:  P Launois; F Tacchini-Cottier; C Parra-Lopez; J A Louis
Journal:  Int Rev Immunol       Date:  1998       Impact factor: 5.311

6.  An in vitro model for infection with Leishmania major that mimics the immune response in mice.

Authors:  M B Soares; J R David; R G Titus
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

Review 7.  The regulation of immunity to Leishmania major.

Authors:  S L Reiner; R M Locksley
Journal:  Annu Rev Immunol       Date:  1995       Impact factor: 28.527

8.  Analysis of cytokine mRNA levels in interleukin-4-transgenic mice by quantitative polymerase chain reaction.

Authors:  C Platzer; G Richter; K Uberla; W Müller; H Blöcker; T Diamantstein; T Blankenstein
Journal:  Eur J Immunol       Date:  1992-05       Impact factor: 5.532

9.  Effects of IL-12 on in vivo cytokine gene expression and Ig isotype selection.

Authors:  S C Morris; K B Madden; J J Adamovicz; W C Gause; B R Hubbard; M K Gately; F D Finkelman
Journal:  J Immunol       Date:  1994-02-01       Impact factor: 5.422

10.  Interleukin (IL)-6 directs the differentiation of IL-4-producing CD4+ T cells.

Authors:  M Rincón; J Anguita; T Nakamura; E Fikrig; R A Flavell
Journal:  J Exp Med       Date:  1997-02-03       Impact factor: 14.307
View more
  12 in total

1.  CXCL10/gamma interferon-inducible protein 10-mediated protection against Leishmania amazonensis infection in mice.

Authors:  Rene E Vasquez; Lynn Soong
Journal:  Infect Immun       Date:  2006-09-18       Impact factor: 3.441

Review 2.  Pro- and anti-inflammatory cytokines in cutaneous leishmaniasis: a review.

Authors:  Nahid Maspi; Amir Abdoli; Fathemeh Ghaffarifar
Journal:  Pathog Glob Health       Date:  2016-09-23       Impact factor: 2.894

3.  Keratinocytes determine Th1 immunity during early experimental leishmaniasis.

Authors:  Jan M Ehrchen; Kirsten Roebrock; Dirk Foell; Nadine Nippe; Esther von Stebut; Johannes M Weiss; Niels-Arne Münck; Dorothee Viemann; Georg Varga; Carsten Müller-Tidow; Hans-Joachim Schuberth; Johannes Roth; Cord Sunderkötter
Journal:  PLoS Pathog       Date:  2010-04-29       Impact factor: 6.823

4.  The IL-6-deficient mouse exhibits impaired lymphocytic responses to a vaccine combining live Leishmania major and CpG oligodeoxynucleotides.

Authors:  Wenhui Wu; Luise Weigand; Susana Mendez
Journal:  Can J Microbiol       Date:  2009-06       Impact factor: 2.419

5.  Recombinant Leishmania major secreting biologically active granulocyte-macrophage colony-stimulating factor survives poorly in macrophages in vitro and delays disease development in mice.

Authors:  Carole Dumas; Anthony Muyombwe; Gaétan Roy; Claudine Matte; Marc Ouellette; Martin Olivier; Barbara Papadopoulou
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

6.  Accelerated control of visceral Leishmania donovani infection in interleukin-6-deficient mice.

Authors:  Henry W Murray
Journal:  Infect Immun       Date:  2008-06-23       Impact factor: 3.441

7.  Infection of Human Neutrophils With Leishmania infantum or Leishmania major Strains Triggers Activation and Differential Cytokines Release.

Authors:  Rafeh Oualha; Mourad Barhoumi; Soumaya Marzouki; Emna Harigua-Souiai; Melika Ben Ahmed; Ikram Guizani
Journal:  Front Cell Infect Microbiol       Date:  2019-05-10       Impact factor: 5.293

8.  Interleukin 1alpha promotes Th1 differentiation and inhibits disease progression in Leishmania major-susceptible BALB/c mice.

Authors:  Esther Von Stebut; Jan M Ehrchen; Yasmine Belkaid; Susanna Lopez Kostka; Katharina Molle; Jurgen Knop; Cord Sunderkotter; Mark C Udey
Journal:  J Exp Med       Date:  2003-07-14       Impact factor: 14.307

9.  2,3,7,8-tetrachlorodibenzo-p-dioxin slows the progression of experimental cutaneous Leishmaniasis in susceptible BALB/c and SCID mice.

Authors:  Gregory K DeKrey; Riane E Teagarden; Jerica L Lenberg; Richard G Titus
Journal:  PLoS One       Date:  2013-10-01       Impact factor: 3.240

10.  Cathepsin B-Deficient Mice Resolve Leishmania major Inflammation Faster in a T Cell-Dependent Manner.

Authors:  Orhan Rasid; Véronique Mériaux; Erin M Khan; Chloé Borde; Ioana S Ciulean; Catherine Fitting; Bénédicte Manoury; Jean-Marc Cavaillon; Noëlle Doyen
Journal:  PLoS Negl Trop Dis       Date:  2016-05-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.